Retatrutide is a novel therapeutic/treatment/medicine agent under investigation for the management/treatment/control of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists/glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide agonists, which work by stimulating/activating/enhancing the r

Arriving in the landscape of obesity therapy, retatrutide website presents a unique method. Unlike many existing medications, retatrutide operates as a dual agonist, at once targeting both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) receptors. This concurrent stimulation encourages various beneficial effects, includ